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Abstract
The chapter describes in detail the pathogenetic role of desynchronosis in the develop-
ment of cerebrovascular diseases (CVD). The data of domestic and foreign literature on 
the study of desynchronosis are presented. The role of melatonin in the regulation of 
circadian rhythms (CR) is shown. Pathological changes in CR affect sleep disturbance, 
emotional and cognitive disorders. It is demonstrated the need of the further study of the 
prevalence and structure of desynchronosis in patients with CVD. The search of the most 
significant factors of desynchronosis development in patients with vascular diseases is 
of great scientific and practical significance. The importance of creating and introducing 
diagnostic and therapeutic algorithms for chronodiagnostics and chronotherapy of CVD 
into everyday practical activities. The effectiveness of melatonin for the normalization 
of sleep and CR in patients with insomnia, acute stroke, depressive disorders is shown. 
Complex therapy of the patients with CVD taking into account chronobiological disor-
ders allows to eliminate the adverse effect of sleep disorders and CR on the regulation of 
the cardiovascular system and improve the efficiency of rehabilitation.
Keywords: circadian rhythms, desynchronosis, chronobiology, SCN, melatonin, 
cerebrovascular disease, stroke, sleep disorders, cognitive disorders, phototherapy, 
chronodiagnostic, chronotherapy
1. Introduction
Physiological processes in living systems undergo rhythmic fluctuations, called biological 
rhythms. Among the great variety of biological rhythms in maintaining the health and func-
tioning of the organism, circadian rhythms (CR) with a period of oscillations of about 24 hours 
are particular important. Evolutionally formed synchronization of the CR as an indicator of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
internal and external synergism, indicates a health status [1]. In the case of discrepancy of the 
CR, there is desynchronosis – a form of circadian pathology, a nonspecific manifestation of 
pathological conditions characterized by changes in the structure of the rhythm: an increase 
(decrease) in amplitude; inversion of acrophases; change the duration of the period [2]. The 
manifestation of many diseases, such as myocardial infarction, stroke, sudden death, etc., is 
closely associated with certain periods of the day [3–5]. The diurnal rhythms of biochemical 
processes and physiological functions are synchronized in time, or synchronous. Thus, the 
number of heart rate (HR) and respiration rate are correlated as 4:1 (72:18, 80:20), that ensures 
optimal oxygen supply to tissues and is consistent with the rhythms of metabolism. There 
are several theories about the nature of endogenous factors. In 1976, the chronohypothesis 
was developed. According to it there is a site in the DNA structure – “chronon,” controlling 
biorhythms. According to the multi-oscillator model of biorhythms, there are many drivers of 
rhythm-pacemakers in the body [6].
External factors of general synchronization include geophysical factors: photoperiods (day-
night), fluctuations in the geomagnetic field of the Earth, changes in the temperature of the 
environment, etc. For a modern person, the change in the phylogenetically formed stereotype 
under the influence of social factors is very important [7].
In the process of evolution, complex mechanisms of nervous and humoral regulation of bio-
rhythms, their optimal synchronization were developed. The launching of circadian oscilla-
tions and their interconnection is carried out by the activity of the central nervous mechanism 
performing the pacemaker function, which is realized through the humoral regulating link 
[2]. Light is the main factor that determines the activity of suprachiasmatic nuclei (SCN) as a 
biological clock. The information on the light mode is fed into the SCN from the retina of the 
eye. They also receive signals from other parts of the brain (afferent inputs) and send impulses 
to various brain structures (efferent inputs) [8].
Through the efferent pathways, the SCN are involved in the regulation of the rhythmic activ-
ity of the endocrine system, blood circulation, eating behavior and other functions. Another 
structure important for the rhythmic organization of functions is the epiphysis – neuroendo-
crine transducer, an organ that transmits information about the illumination of the environ-
ment from the nervous system to the endocrine. Biologically active substance-melatonin is 
synthesized in epiphysis cells [9].
There are different methods for detecting biorhythmological personality: measuring body 
temperature, blood pressure, heart rate, breathing, sleep-wake cycle, metabolic rate dur-
ing the day, determining the level of melatonin in the blood or its metabolites in saliva 
or urine [10]. The prevalence of sleep and wakefulness disturbances in patients with car-
diovascular diseases (CVD) is very high. After a stroke, patients often experience sleep 
disorders such as insomnia, daytime sleepiness, fatigue, behavioral disturbances in the 
sleep phase with rapid eye movements and the restless legs syndrome, obstructive sleep 
apnea syndrome [11–16].
To detect sleep disorders, semi-quantitative scales and questionnaires, polysomnography are 
used [10]. Examination of Daily blood pressure and Holter monitoring of ECG allow to estab-
lish violations of daily dynamics of blood pressure and heart rate. Holter monitoring of ECG 
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enables to evaluate the circadian index (CI), which is an informative method for assessing 
circadian diurnal fluctuations in the heart rhythm [17].
The study of CR in patients with CVD has a great practical interest, since CRs are highly sensitive 
to various types of external influences and their disturbances can be the first symptoms of begin-
ning abnormalities in the vital activity of the organism. There is a lot of data on the existence of 
chronobiological patterns in the development of stroke and myocardial infarction [11–16, 18–26].
The great scientific and practical interest is the study of the chronotropic activity of melato-
nin, the leading biochemical marker of CR. There is clear CR of melatonin production in the 
epiphysis and suppression of its secretion in the light [8].
The role of melatonin in the regulation of diurnal fluctuations of blood pressure is proved 
[27]. It has anti-inflammatory and antioxidant, as well as possible epigenetic activity [28, 29]. 
A number of studies have shown the effectiveness of melatonin for normalizing sleep and cir-
cadian rhythms in patients with insomnia, acute stroke, depressive disorders, arterial hyper-
tension, etc. [29–35]. Chronotropic or rhythm-organizing activity of melatonin determines 
the origin of two leading, official indications for its use: treatment of sleep disorders and 
desynchronosis [29, 31, 36].
The analysis of published data shows the high scientific and practical relevance of further 
study of chronobiological disorders in patients with diseases of the cardiovascular system. It 
allows to reveal the pathogenetic relationship of comorbidity of disorders and to substantiate 
complex approaches to therapy [37–39].
2. Morphofunctional, molecular, genetic and biochemical basis of 
circadian rhythm regulation
2.1. Morphofunctional features of suprachiasmatic nuclei and their connections 
with epiphysis
Circadian rhythms (CR) are physiological and behavioral cycles, which are provided by the 
internal oscillator and remain in the absence of an external “regulator”. The ability to main-
tain a 24-hour rhythm is a fundamental characteristic of a circadian system that allows the 
body to adapt to environmental conditions [1].
Circadian system operates due to four key components:
1. Photosensitive retinal neurons and retinohypothalamic tract through which light signals 
come from the environment;
2. Internal circadian oscillator, generating rhythms and synchronizing them with the 
environment;
3. Signal paths transmitting information from the central regulator to peripheral rhythm 
generators;
4. Peripheral rhythm generators – clock-genes and proteins in peripheral cells [10].
Features of Circadian Rhythms in Patients with Cerebrovascular Diseases
http://dx.doi.org/10.5772/intechopen.75963
81
The central circadian oscillator is the suprachiasmatic nuclei of the hypothalamus (SCN), 
which are heterogeneous in structure and neurochemical organization and are subdivided 
into the rostral and caudal divisions [8, 9].
Most of the SCN neurons are GABA and secrete different peptide neurotransmitters. GABA 
provides a link between the neuronal populations of the ventral and dorsal sections of the 
SCN. It participates in stabilizing the activity of the SCN and maintaining high-frequency 
oscillations of neurons in the CR. Many of the individual SCN neurons exhibit electrical and 
molecular rhythms in isolation, but the rhythms are weaker and less stable [8–10].
It is found, that light stimuli trigger the intra- and intercellular cascade of gene expression 
first in the center of the SCN, whence elements of peripheral parts are involved in the process 
through the GABA-ergic signaling pathways. Specific neuropeptides, gap junctions, astro-
cytes and GABA-ergic signaling realize interrelation between the SCN neurons. Vasoactive 
intestinal peptide (VIP) and arginine-vasopressin (AV), involved in the regulation of rhythms, 
are most studied. Studies show that VIP maintains and synchronizes rhythms of the SCN, 
while AV participates in maintaining high amplitude of the output signal from the SCN and 
in re-input pulse modulation [8–10].
Rhythmicity and synchronism of the nuclei operation in the diurnal regime is maintained 
in this way. The physiological role of the SCN, which reduces to the generation of circadian 
signals and the subordination of the activity of neighboring brain structures and peripheral 
organs, is entirely determined by the nature of their afferent and efferent connections [8].
Among the afferent projections of the SCN, the retinohypothalamic tract, which provides the 
nucleus with information about the state of photoperiodic processes, is of particular impor-
tance. It transmits to the SCN the main stream of optical impulses and is represented by col-
laterals of retinal ganglion cells. Its damage affects the dynamics of the CR in the form of a 
phase shift [8].
Another significant afferent input for SCN is the ascending axons of the neurons of the seam 
nuclei projecting here. The existence of direct raphohypothalamic tracts explains the high 
content of serotonin in the SCN. The electrical stimulation of the seam nuclei clearly inhibits 
the rhythmic of the hypothalamic neurons. In experiments on isolated SCN neurons, agonists 
and antagonists of serotonin receptors when applied locally, simulating the effect of light, 
were shown to be able to shift the phase of CR cells [8, 9].
The SCN forms neural connections with the nuclei of the stem, responsible for the regulation 
of sleep and wakefulness processes [10]. The SCN have direct connections with supraven-
tricular and preoptic regions, dorsomedial divisions of the hypothalamus, arcuate and para-
ventricular nuclei. The direct and inverse relations of the SCN with the various elements of 
the limbic system and the motor centers have great functional significance. In particular, some 
nuclei of the amygdala and septa are projected onto the SCN [40].
A special place in the temporal organization of adequate adaptive behavior and the genesis 
of affective disorders is attributed to the interaction of the SCN with the epiphysis and emo-
tiogenic limbic structures. Epiphysis is an important relay station and the leading link in the 
realization of circadian signals in relation to different functional indicators [8, 9].
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The SCN almost entirely determines dependence of brain activity on the state of external 
illumination. During the day, light entering the retina activates its photosensitive ganglion 
cells, the information from which is transmitted through the retinohypothalamic tract and 
further into the SCN. Signals from the SCN are transmitted to the paraventricular nucleus 
of the hypothalamus, and further, trough the intermediolateral column of the spinal cord, 
reach the upper cervical ganglion. Sympathetic postganglionic noradrenergic fibers innervate 
melatonin-secreting cells in the epiphysis. Norepinephrine acts on postsynaptic beta-1 and 
alpha-1-adrenergic receptors in the cells of the epiphysis, which trigger the synthesis of mela-
tonin. There is a clear daily periodicity: the production of melatonin begins with the onset of 
darkness, reaches a maximum at midnight and stops in the light. In the light phase of the day, 
this process is replaced by an increased synthesis of serotonin [7, 8, 41].
There are reciprocal relationships between the SCN and the epiphysis, and melatonin is able to 
make certain corrections to circadian dysrhythmia, including inhibiting the discharges of SCN 
neurons. Under the influence of melatonin, the CR phase shift is also described in humans, 
which allowed recommending it for the correction of latitudinal desynchronosis [29, 41].
By obeying the signals of the SCN, the epiphysis through melatonin can directly interfere 
with the functional activity of the limbic structures of the brain. Hyperactivity of the latter 
causes the development of dysrhythmia, accompanied by an increased level of anxiety. With 
steady stressing, the anxiety transforms into a depressive state. The SCN due to its direct 
efferent projections into the subcortical limbic nuclei, and indirectly (via melatonin) limits 
hippocampal excitability. Probably, this is one of the ways to realize anti-anxiety properties 
of the epiphyseal hormone. Thus, the disturbance of the interaction of SCN with the epiphysis 
is one of the pathogenetic factors of anxiety and depression [42, 43].
In addition to managing the CR of the psychoemotional state, along with other circadian fluc-
tuations, the SCN provide regulation of the basal cycle of calm-activity. It is known, the patients 
with depression are characterized by night sleep disturbance and phase structure of sleep disor-
der. One of the probable causes is legitimately sought in violation of the normal activity of the 
central pacemaker. It has been established that the SCN lesion in animals along with other CR 
disturbance significantly disturbs the sleep [42, 43]. Insomnia in humans is often combined with 
neurodegenerative pathology (Alzheimer’s disease (AD), etc.), which is usually accompanied 
by the SCN lesion. On the other hand, a rhythmic change in the states of sleep and wakefulness 
is quite an autonomous process and persists in people deprived of external time sensors, which 
emphasizes the dependence of sleep on the activity of the leading pacemaker [44–48].
According to modern concepts, the periodic nature of the sleep-wake cycle is determined by 
the co-operation of the brainstem formations in the ascending awakening system of the brain 
and the hypnogenic pathways, the impulse from which, following to the forebrain, along 
with other structures, involves ventrolateral preoptic nuclei. The latter provide alternating 
excitation of activating and inactivating (hypnogenic) mechanisms with rhythmic change of 
sleep and wakefulness states during 24 hours, demonstrating a switching function. The weak-
ness of the rhythm-organizing properties of the SCN can be determined by the pathological 
reorganization of intranuclear processes at the molecular level. An important reason for this 
is often the changes in the circadian oscillations of the clock genes [49, 50].
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Figure 1. Мelatonin synthesis scheme.
2.2. Molecular mechanisms of circadian oscillations
The molecular basis for the CR regulation is provided by the hour genes, whose work is car-
ried out on the principle of loops of positive and negative feedback. The BMAL1 and CLOCK 
proteins accumulated during the day form the BMAL1/CLOCK complex. The BMAL1/CLOCK 
dimer activates the transcription of the PER genes (PER1, PER2, PER3) and CRY (CRY1, CRY2). 
Synthesized PER and CRY proteins also form a PER/CRY dimer acting on the principle of neg-
ative feedback. PER/CRY moves to the cell nucleus and inhibits the activity of the BMAL1/
CLOCK complex, which leads to a decrease in the expression of PER and CRY proteins. During 
the night, the PER/CRY complex is destroyed, and the 24-hour cycle begins anew [49, 50].
Another clock gene involved in the regulation of this cycle is REV-ERB-alpha. The BMAL1/
CLOCK complex activates the transcription of the gene, which leads to the accumulation in 
the cell of the protein REVERB-alpha. The REVERB-alpha protein in turn inhibits the tran-
scription of the BMAL1 gene and presumably the CLOCK and CRY1 genes [51].
2.3. Melatonin involvement in the circadian rhythms regulation
The leading regulator of biological rhythms is the epiphyseal hormone melatonin (N-acetyl-
5-methoxytryptamine) acting on circadian systems via MT1- and MT2-melatonin receptors in 
the hypothalamus SCN [1, 28, 29].
The melatonin donor is the amino acid tryptophan, which participates in the synthesis of 
the neurotransmitter serotonin, which under the influence of the enzyme N-acetyltransferase 
turns into melatonin (Figure 1) [29].
Melatonin is an indole derivative of serotonin and is produced at night with the participation 
of N-acetyltransferase and hydroxyindole-O-methyltransferase enzymes [29].
Extrapineal sources of melatonin synthesis are enterochromaffin cells of the gastrointestinal tract 
(EC-cells), the main depot cells of serotonin (contain up to 95% of all endogenous serotonin). The 
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synthesis of this hormone has been found in many neuroendocrine cells of the airways, lungs, 
in the cortical layer of the kidneys and along the boundary between the cortical and medullary 
layer of the adrenal glands, under the hepatic capsule, in the paraganglia, ovaries, endometrium, 
prostate gland, placenta, gallbladder and inner ear. In recent year’s studies, melatonin synthesis 
is found: in blood cells – mast cells, lymphocytes – natural killers, thrombocytes, eosinophilic 
leukocytes, in the thymus, pancreas, cerebellum, retina. Functionally, many melatonin-produc-
ing cells belong to the so-called diffuse neuroendocrine system – a universal system for adapt-
ing and maintaining the body’s homeostasis. Thus, two links of melatonin-producing cells are 
distinguished: central (includes the pineal gland and cells of the visual system), in which the 
rhythm of melatonin secretion coincides with the rhythm of light-darkness, and peripheral – all 
other cells where the secretion of the hormone does not depend on illumination [1, 2, 29].
Melatonin is transported by serum albumin, after liberation from albumin it binds to specific 
receptors on the membrane of target cells, penetrates into the nucleus and performs its action 
there. The biological half-life of melatonin is 45 minutes. This makes it difficult to collect mate-
rial for research purposes. Melatonin is rapidly hydrolyzed in the liver and excreted in the 
urine (80–90%), the main metabolites are 6-hydroxymelatonin-sulfate (6-SOMT) and 6-hydrox-
yglycuronide. The concentration of melatonin metabolites in saliva and/or urine correlates well 
with the total level of melatonin in the blood during the sampling period [1, 10, 30].
It has been found that the effect of melatonin is realized through MTNR1A (MT
1
) receptors, 
which are expressed mainly on the cells of the anterior lobe of the pituitary gland, the hypo-
thalamus SCN and in many peripheral organs; as well as MTNR1B (MT2) receptors, expressed in some parts of the brain, in the retina and in the lungs. The nuclear receptors of melatonin of 
the subfamily RZR/ROR of retinoid receptors have recently been discovered. Many immuno-
stimulatory and antitumor effects of melatonin are mediated through them [52].
During the first years of life, peak concentrations of melatonin increase and reach a maximum 
by 2–4 years, after which they begin to decrease and reach the plateau by the time of puberty. 
The secretion of melatonin continues to decrease yearly after the end of puberty [10]. Both 
basal and peak concentrations of melatonin decrease with age, the daily curve of melatonin 
secretion is smoothed and the peak of night secretion decreases [10, 52–54].
The daily fluctuations in the melatonin level in the blood (melatonin curve) looks like the 
following. Its concentration is minimal by day (1–3 pg./ml), it starts to increase 2 h before 
the usual time for going to sleep (if there is no bright light). After turning the light off in the 
bedroom, the concentration of melatonin increases rapidly (up to 100–300 pg./ml). In the pre-
hour hours, a recession usually begins, which ends after awakening. For each person, the 
melatonin curve is stable from night to night, while in different people of the same gender and 
age the curves differ significantly, so one can speak of an individual curve [10, 52].
In a number of experiments on animals, the antioxidant properties of melatonin have been demon-
strated. The mechanism of antioxidant action is manifested in the fact that melatonin has a pro-
nounced ability to bind free radicals, including those formed during peroxidation of hydroxyl 
radical lipids, and exogenous carcinogens, and it also activates glutathione peroxidase, a factor 
protecting the body from free radical damage. The main functions of the melatonin antioxi-
dant action are aimed at protecting DNA [10, 29, 52, 55]. To a lesser extent on the protection of 
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proteins and lipids. Its addition to the ration of rats resulted in an increase in life expectancy 
and testosterone levels in males [52, 56]. In the study of V.A. Lesnikov and W. Pierpaoli trans-
plantation of the pineal gland from young to older individuals increased their lifespan by 42% 
and, conversely, transplantation of the epiphysis of older individuals reduced it by 29% [57]. 
Against the background of the use of melatonin in aging mice, not only the duration of life 
but also the volume of thymus, adrenals and testes increased, which was accompanied by an 
increase in the level of testosterone and thyroid hormones in the blood. Thus, a decrease in 
melatonin synthesis probably plays an important role in aging processes [53].
Reducing melatonin concentrations in the elderly is probably one of the main factors in the 
development of age-related neurodegenerative diseases. A retrospective analysis of 6-year-old 
data in patients with depression revealed a disruption in the regulation of the synthesis and 
metabolism of catecholamines, neurotransmitters, melatonin and immunological proteins [42]. 
It has also been shown that melatonin supports the optimal mitochondrial membrane potential 
and preserves mitochondrial functions. In addition, mitochondrial biogenesis and its dynam-
ics are also regulated by melatonin. Mitochondrial dynamics demonstrates an oscillatory pat-
tern that corresponds to the CR of the secretion of melatonin in the pinealocytes and, possibly, 
in other cells [28, 52, 55]. A number of recent scientific studies have identified the neuroprotec-
tive effect of melatonin, which is manifested by affecting the proliferation and differentiation 
of neural stem cells, increasing the content of myelin and oligodendrocytes [58, 59].
In other studies, melatonin demonstrated a neuroprotective effect in neurodegenerative dis-
eases. Melatonin reduces the toxicity of beta-amyloid and prevents the death of cells in experi-
mental AD models, and also reduces oxidative stress in PD models [44–46, 48].
In addition, the experiment demonstrated the effect of melatonin on the proliferation and differen-
tiation of stem nerve cells. Depending on the dose of melatonin introduced into the mice cortex, the 
proliferation rate of oligodendrocytes, the percentage of the main myelin protein, as compared 
with the control group, increased. Thus, melatonin may have a potential therapeutic effect for 
some neurological diseases associated with oligodendrocyte pathology and myelinopathy [59].
In recently published papers it is reported that melatonin synchronizes not only central but 
also peripheral biorhythms, which allows to synchronize biological functions by means of CR 
with respect to periodic changes in the environment and, therefore, facilitates adaptation of 
the individual to the external environment [28, 52].
The large number and diversity of the main effects of melatonin opens up important pros-
pects for measuring the level of melatonin as a biomarker for the purpose of clinical, preven-
tive and therapeutic use [10, 32].
3. Violation of CR and cerebrovascular diseases (CVD)
3.1. Desynchronosis as a risk factor for stroke
The presence of chronobiological disorders in patients with CVD is noted by many research-
ers [11–26, 60–86].
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In a comparative analysis of autonomic control of the rhythms of the cardiovascular system 
(CVS) in young and elderly healthy people in Ukraine, it was shown that circadian regulation 
of blood pressure and heart rate is impaired in elderly people. [25].
There are reports that chronobiological disorders are detected in patients with arterial hyper-
tension [70–72], diabetes mellitus [73–75], cardiac ischemia [11, 12, 14, 61, 66], dementia [67–70], 
etc. Nowadays there is a lot of data on the existence of chronobiological patterns in the devel-
opment of stroke and myocardial infarction (MI) [11, 12, 14].
It is known that Ischemic stroke (IS) develops more often in the early morning hours [10]. This 
may be due to an increase in the activity of the coagulating system of blood at this time [71], 
as well as with a violation of the daily regulation of blood pressure and heart rhythm in these 
patients [72, 73]. In epidemiological studies, increased frequency of sudden cardiac death, MI 
and transient myocardial ischemia, pulmonary embolism and critical ischemia of the lower 
extremities, as well as rupture of the aortic aneurysm at dawn.
The second small peak of incidence is noted in the early evening [74]. European researchers 
point to an increased incidence of stroke and MI in winter [75].
In the epidemiological study conducted in Hawaii, it was found that the MI in local popula-
tion of the Caucasoid race occurs most often between 04:00 and 12:00, and in Japanese visitors 
– from 12:00 to 16:00, which corresponds to the morning hours in Japan [76]. Similar daily 
dynamics of MI and stroke development early in the morning and between 12:00 and 18:00 
was noted in a prospective study conducted in India involving 158 elderly patients [77]. Such 
a pattern of development of MI and stroke in the morning can be associated with an increase 
in platelet aggregation capacity in the morning hours with a peak at 09:00 [71–73]. Also in the 
early morning, endothelial cells reduce the synthesis of tissue activator plasminogen, nitric 
oxide and prostacyclin, the tone of the myocytes of the vascular wall is reduced, which pro-
motes thrombosis [71].
In addition, there is a seasonal and cyclical decompensation of the CNS. As a rule, exacerba-
tions occur in the spring and autumn. There is evidence that hemorrhagic stroke (HS) often 
manifests in winter and spring, and IS in summer and autumn [78]. Daylight saving time 
transgresses the CR and shifts the picture of the diurnal variation at the beginning of the 
stroke, but the effect on the IS frequency is unknown.
Effects of 2004–2013 daylight saving time (DST) transitions on IS hospitalizations and in-hos-
pital mortality were studied nationwide in Finland. Hospitalizations during the week fol-
lowing DST transition (study group, n = 3033) were compared to expected hospitalizations 
(control group, n = 11,801), calculated as the mean occurrence during 2 weeks prior to and 
2 weeks after the index week. DST transitions appear to be associated with an increase in IS 
hospitalizations during the first 2 days after transitions. Susceptibility to effects of DST tran-
sitions on occurrence of ischemic stroke may be modulated by gender, age and malignant 
comorbidities [79].
Disorders of CR are associated with an increased risk of IS. A monitoring of blood pressure 
for 5 days after a previous IS or HS, conducted in 50 patients (India), indicates a decrease in 
natural circadian fluctuations with an increase in blood pressure during the night [77].
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According to the Stockholm population cohort study, 48-hour heart rate monitoring in 678 
practically healthy people aged 55–75 years allowed to reveal a statistically significant risk 
of MI development in patients with reduced nighttime heart rate variability. Some authors 
point to a direct relationship between the frequency and severity of MI and the severity of 
violations of daily BP regulation. They divide patients into groups of “dippers” and “non-
dippers”. It was established that the activity of the central link of the sympathetic nervous 
system was increased in patients with “non-dipper”, i.e., those who do not have a decrease 
in blood pressure during night sleep or less than 10% of the daytime sleep. These people 
are less active in endothelium-dependent vasodilation, and a possible cause of high pressure 
is the damage to the baroreceptor reaction. As a result, “non-dippers” are characterized by 
increased sympathetic activity during sleep and, as a consequence, have a high risk of general 
and cardiovascular mortality [80].
The dependence between the amount of brain damage and the degree of decrease in night-
time blood pressure (BP) is established: the greater the amount of brain damage, the less it 
decreases at night. Thus, in patients with lacunar stroke, in contrast to patients with non-
lacunar stroke, a greater BP reduction is detected during monitoring at night. This may indi-
cate the safety of the mechanisms of regulation of circadian rhythms of pressure in the case 
of lacunar stroke [81].
The results of the large clinical trial in Japan with a 24-hour outpatient BP measurement in 515 
patients and parallel magnetic resonance imaging (MRI) of the brain showed that increasing the 
pulse pressure during sleep and mean BP on waking, especially in the elders, are independent 
predictors of MI in elderly hypertensives. In this case, the effect of pulse pressure and the 
mean value of BP on stroke risk differs in separate phases of the sleep-wake cycle. Thus, an 
increase in the pulse pressure for every 10 mmHg. in a sleep independently increases the risk 
of stroke by 43% (p = 0.001), while the average BP index during sleep is not so significant. At 
the same time, the mean BP increase for every 10 mmHg. on waking, independently increases 
the risk of stroke by 48% (p < 0.001), and the level of pulse pressure upon awakening is not 
a significant factor [82]. The study of night-time heart rate variability may have prognostic 
value for the stroke prevention.
Our study with the inclusion of 226 patients with cardiovascular diseases (CVD) has shown a 
high incidence of sleep disorders and desynchronosis in these patients. A comparative analy-
sis of the nature of sleep disorders in patients with cardiological disease (myocardial ischemia, 
essential hypertension) and CVD showed that sleep disorders due to anxiety-depressive dis-
orders prevail in patients with CVD in the structure of detected sleep disorders, and after a 
stroke – sleep disturbances due to desynchronosis. This may indicate deeper violations of the 
adaptive mechanisms regulated by nonspecific brain systems, which leads to disturbances in 
the sympathetic and parasympathetic links in the vegetative status.
Patients with MI also showed sleep disorders, which may indicate the role of cardio-cerebral 
interactions in the regulation of sleep mechanisms.
Patients with CVD showed a decrease in the level of 6-SOMT, among which predominate the 
patients with MI [83, 84]. The presence of cognitive disorders, sleep disorders and chronobiological 
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disorders (daily regulation of heart rhythm and BP) was related with a low level of 6-SOMT 
in daily urine examined [85, 86].
The study of sleep characteristics in patients with CVD revealed high frequency of occurrence 
of sleep disorders and desynchronosis in these patients and their positive correlation with the 
development of behavioral and affective disorders (r = 0.57, p = 0.002), as well as their effect on 
the daily profile of the cardiac rhythm and BP (r = 0.46, p = 0.008). Therefore, timely diagnostic 
and complex psycho-pharmacological correction of sleep disorders and desynchronosis in 
patients with СVD will improve the psychological and emotional status of patients, normal-
ize daily profile of heart rhythm and BP. A positive correlation between desynchronosis and 
stroke was proved (r = 0.39, p = 0.013). This suggests that desynchronosis is a risk factor for 
stroke in patients with CVD [25].
3.2. Stroke and sleep disorders
According to the polysomnographic study sleep disorders in stroke reach 100% of the cases 
and are manifested as insomnia, disturbance of the “sleep-wake” cycle and respiratory dis-
tress in sleep as the type of “sleep apnea” syndrome [87]. It was found that sleep disorder is 
one of the etiological factors of stroke, also increases the risk of recurrent stroke and prevents 
recovery after it [18–25, 62, 87–95].
Large population studies (more than 3000 patients) indicate that a reduction in sleep dura-
tion (less than 6 hours) is associated with an increased risk of hypertension, especially among 
women compared to men, and is stronger in premenopausal women than in postmenopausal 
women. The revealed relationship does not depend on the socioeconomic status, traditional car-
diovascular risk factors and psychiatric comorbidity, and is stronger in premenopausal women. 
Consequently, a decrease in the duration of sleep increases the risk of developing hypertension, 
which can lead to the cardiovascular pathology (СVP) development in women [62].
In the Danish cohort population study over 12 years, which included 20,432 men and women 
aged 20–65 years, a high incidence of CVP was found in people with insufficient duration 
and quality of sleep [15]. In the Australian study, among 218,155 people 45 years of age or 
older, it was found that sleep duration of less than 6 hours and more than 9 hours is associ-
ated with a high risk of diabetes, stroke, hypertension and coronary heart disease (CHD). A 
prospective study of 1986 patients aged 55–69 years (Great Britain) showed that IS is more 
likely to develop in patients with disturbed sleep at night, and MI is associated with increased 
daytime sleepiness [25].
In 2016, scientists from the University Clinic of Essen published a meta-analysis of 29 scien-
tific papers evaluating sleep disorders that may be associated with stroke. A total of 2.343 
patients with IS, HS or transient ischemic attack (TIA) participated in the studies. Sleep dis-
orders in these patients were divided into 2 groups: (1) disturbance of breathing during sleep 
(obstructive sleep apnea); (2) sleep and wakefulness disorders, which reduces the duration of 
sleep. It was revealed that sleep disturbance was observed in 72% of patients with IS, in 63% of 
patients with HS and in 38% of patients with TIA. A lot of patients had a sleep disorder before 
stroke. This allows to believe that sleep disorders increase the risk of stroke [22].
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The authors also proved that not only insomnia, but hypersomnia and restless leg syndrome 
increase the risk of stroke. To date, specific mechanisms for increasing cardiovascular risk 
in restless legs syndrome have been described: (1) periodic movements of limbs in a dream, 
accompanied by a significant increase in the heart rate and BP; (2) fragmentation of sleep and 
lack of sleep, invoking changes in the regulation of nervous and vascular systems, metabo-
lism, oxidative, inflammatory processes; (3) iron deficiency, which creates new risks for CVP 
[90–92].
In general, the exact mechanisms by which sleep disorders can lead to stroke are not dis-
closed. Nevertheless, it is shown that sleep has an important restorative function of the brain 
and affects the processes of neuroplasticity. Sleep disorders can persist after a stroke, and 
without appropriate correction may obstruct the after stroke rehabilitation.
3.2.1. Characteristics of sleep disorders in patients with stroke
Insomnia in stroke patients is characterized by a change in the duration of sleep, frequent 
nocturnal awakenings, lack of satisfaction at night sleep, and the appearance of “heaviness” 
in the head [22, 87]. According to the polysomnographic study, there is an increase in stages 1 
and 2, a decrease in phases 3 and 4 of the slow-sleep phase (SSP), and often a reduction in the 
phase of fast sleep (FSP) [10, 13].
Sleep-wakefulness disorders in patients with stroke are caused by damage of the hypotha-
lamic structures associated with the “internal clock”, or their connections. Clinically mani-
fested by disturbance of night sleep, pathological daytime drowsiness or a combination of 
both. This is more common in multiple lacunar stroke. In patients with severe cognitive 
impairment after stroke, the inversion of the sleep-wake cycle with sleeplessness at night and 
daytime drowsiness is often observed. As a rule, these conditions are accompanied by behav-
ioral disorders. At the same time the patient is nervous, cannot understand where he is, tries 
to get out of bed, go, resists the actions of medical staff. These conditions cause the difficulties 
in rehabilitation of these patients in the hospital [22, 87].
Studies of recent years have shown that obstructive sleep apnea (OSAS) is an independent mod-
ifiable risk factor for stroke. To date, it has been established that respiratory events associated 
with OSAS are involved in cyclical episodes of hypoxemia and hypertension, increased plate-
let aggregation, reduced fibrinolysis, endothelial dysfunction, increased intracranial pressure, 
decreased cerebral blood flow and local cerebral ischemia. In the acute period of IS the incidence 
of OSAS is 36% [93]. Respiratory disturbances in sleep in patients with stroke, cause the worst 
efficiency of the rehabilitation process. It is shown that the presence of OSAS is accompanied 
by greater functional insufficiency and a longer period of hospitalization of patients [94–100].
In general, for all stages and forms of stroke, changes in both the mechanisms of sleep genera-
tion and the mechanisms of its maintenance are typical. The cause of these violations are not 
only the damage and death of brain tissue of a local nature, but also disorders of general and 
local hemodynamics, the appearance of edema and displacement of the brain substance, the 
ingress of blood into the cerebrospinal fluidways, and as a result – the irritation of various 
structures located in the brainstem [18].
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It is believed that the greatest impact on sleep is the nature, size, localization of the process 
and the stage of the disease.
3.2.2. Features of sleep disorders depending on the type, localization of the focus, stage of stroke 
and development time of the stroke
HS in comparison with IS leads to the most severe disorders of night sleep. Characterized by a 
deep reduction in the duration of sleep, frequent and prolonged awakening, an increase in the 
representation of the first stage. However, with a favorable outcome of the disease, the degree 
of recovery of the structure of sleep is faster than in IS. In IS there is a focus of necrotic decay 
of brain tissue, while with hemorrhage, damage occurs as a result of the stratification of brain 
structures with blood. Therefore, the restoration of both the clinical picture and night sleep is 
better and for a shorter period in HS [22, 101].
The size of the focus of stroke plays a significant role in the formation of sleep disorders. A large 
focus leads to a common swelling of the hemisphere, sometimes even the opposite, the emer-
gence of processes of compression of the brain stem. Hence the most severe disorders of sleep 
are observed in large foci of stroke. In the available studies it was shown that the maximum 
proximity of the focus to the median structures and the liquor-bearing pathways (medial 
arrangement) leads to more severe sleep disorders. Not only quantitative but also qualita-
tive changes in the structure of sleep are noted. Thus, the medial focus with the capture of 
thalamic structures is characterized by the disappearance on the side of the lesion of “sleepy 
spindles” (electroencephalographic signs of stage II of sleep). The lateral processes are accom-
panied by less severe sleep disorders [19].
The localization of the lesion in the hemispheres or in the brain stem causes specific changes 
in the structure of sleep. Greater disorders observed in the right hemispheric processes: decreases 
the duration of d-sleep and FSP, lengthen the waking period and stage I, the duration of 
falling asleep; the number of awakenings increases. The reason for such sleep disorders in 
right hemisphere patients is the damage of the deep mechanisms of the relationship between 
the right hemisphere and the hypnogenic structures of the brain. In addition to sleep disor-
ders, these patients notice marked changes in vegetative regulation, which is manifested by 
tachycardia, various types of cardiac arrhythmia, high BP numbers. The left hemisphere is most 
closely associated with the activating systems of the brain. There is an opinion that this is the 
cause of frequent impairment of consciousness in left hemispheric strokes [19].
When a process occurs in the area of the pons, the duration of the FSP dramatically decreases, 
and its latent period increases. Bulbar symptoms are accompanied by a decrease in the dura-
tion of d-sleep.
The acute stage of stroke (week 1) is characterized by a number of clinical and polysomnographic 
features. In this period, there are difficult to control hemodynamic, general cerebral and 
local neurological processes. Depending on the direction of the disease, a different picture is 
observed in polysomnography. Severe disturbances of consciousness (sopor, coma), as a rule, 
are accompanied by a diffuse slow wave activity, which excludes the possibility of isolating 
individual stages of sleep. The emergence of separate stages and sleep phenomena against 
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a background of diffuse cerebral electrical activity is a prognostically favorable sign. With 
conserved consciousness in the most acute period, polyphase and inversion of the “sleep-
wakefulness” cycle due to circadian disorders are often enough. In the first case, patients 
fall asleep several times during the day; in the second – the cycle “sleep-wakefulness” shifts, 
there are daytime sleep and night wakefulness. In the presence of general cerebral symptoms, 
frequent awakenings, a decrease in d-sleep and the absence of FSP are observed [19].
The structure of sleep in patients with stroke also differs depending on the time of its onset. 
A characteristic feature for a stroke that occurred during sleep is a high FSP presence, which, 
along with the “vegetative storm” in this phase, can be one of the causes of stroke at night. 
According to statistics, in patients with a “morning stroke” in comparison with “daytime” 
and “night”, the shortest FSP time is noted [19].
Investigation of the night sleep structure in patients with stroke showed the premorbid sleep 
problems (frequent awakening, long sleep, dissatisfaction with sleep, early awakening), 
which are associated with worse parameters of sleep quality after stroke [18, 101]. Thus, the 
initial feature of the regulation of the “sleep-wake” cycle influences the formation of struc-
tural changes in sleep after stroke.
3.2.3. Sleep disorders and recovery from stroke
The quality of sleep can serve as a prognostic criterion for the possibility of recovering patients 
with stroke. So, changes in the structure of sleep in the acute period of stroke have an impor-
tant prognostic value. If a normal pattern of sleep does not return within 7–10 days after a 
stroke, the prognosis is considered unfavorable [10]. A multicenter-observational and cor-
relation study involving 280 patients with mild and moderate severity of stroke showed ini-
tially high rates of affective and cognitive impairment (26.9%) and sleep disorders (567%) in 
patients in the early recovery period of stroke. In patients with sleep disorders, regardless of 
the severity of the stroke, recovery of the neurological deficit, cognitive functions proceeded 
more slowly compared to patients without sleep disorders, primarily with regard to improv-
ing the Berg balance scale. It was found that sleep disturbance after stroke has a negative 
effect on functional recovery, especially on improving the balance in the group of moderate 
stroke [102].
Restoring and maintain a natural biorhythm sleep-wakefulness with the use of physical and 
medicinal methods for the stroke prevention and treatment are recommended.
Currently, in the correction of sleep in patients with stroke, the leading place is the drug ther-
apy. The strategy of pharmacotherapy of sleep disorders in patients with stroke is reduced 
not to achieving a one-time hypnogenic effect, but to normalizing the adaptive-compensatory 
potential of the central nervous system. Based on such positions the advantages of melatonin 
as a hypnotic are estimated. As a natural chronobiotic, melatonin synchronizes CR, provides 
normalization of desynchronized CNS activity. Therefore, the correction of sleep disturbances 
with melatonin (as opposed to “classical” hypnotic drugs) becomes not only as the result of 
a hypnogenic effect, but due to normalizing the activity of various brain structures that sup-
port the processes of complex central regulation. Exogenous melatonin, taken in the evening, 
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stabilizes the work of the SCN and marks the starting point for determining the subjective 
dark time of the day [29, 31, 32].
A number of clinical studies have shown the positive effect of melatonin on daytime sleepi-
ness, a reduction in the period of falling asleep and the number of nocturnal awakenings, the 
restoration of disturbed sleep initiation in patients with stroke [33–37].
In one of the major studies to correct the disturbances of the sleep-wake cycle, patients with 
stroke were prescribed a melatonin (Melaxen, Unipharm, Inc., USA) in a dose of 3 mg at 
bedtime for 10 nights. Against the background of taking Melaxen, there was an increase in 
the time of night sleep and a decrease in the number of sleep episodes during the day. That 
is, there was a normalization of the distribution of the sleep time in the 24-hour sleep-wake 
cycle [35].
When studying the condition of the CNS in 60 patients in the acute period of stroke, it was 
found that the inclusion in the scheme of complex therapy of Melaxen at a dose of 6 mg per day 
contributed to a faster and more complete recovery of motor disorders, improvement of the 
cranial nerves function. In addition, while Melaxen’s administration, a rapid normalization of 
a number of electrophysiological parameters during the recording of an electroencephalogram 
was observed: changes in activity in the EEG delta and theta bands, which were accompanied 
by a change in the BIS and ITA indices [104].
We evaluated the effectiveness of chronotherapy (Melaxen) on the dynamics of sleep dis-
orders, cognitive and emotional disorders, neurotrophic brain factor (BDNF), the level of 
melatonin secretion (6-SOMT) in patients in the early recovery period of cerebral stroke. 112 
patients were examined in the early recovery period of the stroke (mean age 58.0 ± 9.74 years). 
The main groups of patients, along with the standard treatment regimen, received photother-
apy and Melaxen 3 mg per day for 3 months. The effectiveness of the therapy was assessed 
by the dynamics of sleep disorders, psychoemotional status, the concentration of the neuro-
trophic brain factor BDNF, the level of 6-SOMT in the urine. The study demonstrated a high 
effectiveness of chronotherapy (Melaxen, phototherapy) in the rehabilitation of patients in 
the early recovery period of stroke. The presence of cognitive disorders, sleep disorders and 
emotional disorders correlated with a low level of 6-SOMT in urine in the patients.
Complex therapy with Melaxen, revealed a significant increase in the level of excretion of 
6-SOMT in patients by the end of the 3-month follow-up period. An increase in the concen-
tration of BDNF after 3 months of therapy and throughout the observation period may indi-
cate activation of the synthesis of growth regulators and differentiation of the nervous tissue 
(neurotrophic effect). Increased concentrations of BDNF, 6-SOMT in the urine correlated 
with improved sleep, cognitive and emotional status, motor disorders and quality of life of 
patients.
In another our study, with 132 outpatients (59 men and 73 women) aged 61.4 ± 4.7 years in 
the early recovery period of ischemic stroke (IS), OSAS was detected in 52 (39.4%) cases. 
Light and medium OSAS was diagnosed in 49 cases, in 3 patients – severe OSAS, which 
required selection of CPAP therapy. Patients with OSAS of mild and moderate severity (49 
persons) were divided into 2 groups, comparable by sex, age and neurological manifestations. 
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All patients received drug therapy according to the standards of specialized medical care; 
positional therapy, exercise therapy, mechanotherapy, psychotherapy. Patients of the main 
group (25 people, mean age 59.5 ± 4.8 years), along with the treatment described above, 
received melatonin 3 mg per day for 30–40 minutes before sleep for 3 months and used 
intraoral repositioning applicators. Patients in the control group (24 patients, mean age 
62.3 ± 4.2 years) were prescribed only standard therapy. Already a month after the start of 
therapy, the patients of the main group had a positive dynamic: decrease in daytime sleepi-
ness, snoring, and an expression of morning fatigue. After 3 months, the sleep characteristics 
of the patients in the main group were statistically significant (p < 0.05), differed from the 
control group by a shorter sleep time (8.8 ± 3.2 vs. 20.9 ± 16.7 minutes), an extended total sleep 
duration (431, 0 ± 34.7 vs. 386.9 ± 90.4 minutes), greater representation of the 4th stage of slow 
sleep (12.6 ± 3.5% vs. 8.1 ± 6.7%) and a lower total waking time (8, 0 ± 4.2 vs. 37.5 ± 12.8 min-
utes). After 6 months of therapy, positive changes in the polysomnography index remained, 
a reduction in the frequency of obstructive events in the patients of the main group as com-
pared with the control.
Simultaneously with the normalization of sleep, the positive dynamic of clinical and neuro-
logical indicators was demonstrated. By the 3rd month. Therapy, the cumulative cognitive 
parameters of the MoCA test, the psychoemotional functions and the quality of life of the 
patients in the main group were statistically significantly improved, in contrast to the controls.
Detailed study of night sleep in patients with stroke is not only of scientific interest, but also 
has serious practical significance in matters of prognosis, secondary prevention, as well as 
medical and rehabilitation measures.
The use of a standardized criterion for assessing the dynamics of the CR of the heart rate 
extends the diagnostic capabilities, reveals new pathogenetic links of the CVD, optimizes the 
treatment regimen for patients with CVP. Identification of CR abnormalities in the manage-
ment of BP and heart rhythm in combination with sleep disturbances allows to include mela-
tonin drugs in therapy.
Thus, the detection of sleep disorders and desynchronosis in patients with CVD requires that 
medical, psychological and social aspects is included in complex therapy.
It is advisable to use the following chronotherapeutic approaches:
1. Change of daily regime according to a chronotype of the patient and reduction of a mode 
of work and rest in conformity with natural photoperiods;
2. Use of physiologically appropriate diet;
3. Optimization of the motor activity regime with the recommendation of walking outdoors 
and moderate insolation;
4. Inclusion of photo- and color therapy in the complex of rehabilitation;
5. The Chronopharmacological approach in Drug Administration.
6. Melatonin administration at a dose of 3 mg per day. For 30–40 minutes before bedtime.
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4. CR disorders in patients with DVB and development of cognitive 
disorders
At present, there is enough evidence on the association of early and progressive CR disor-
ders, changes in quality and sleep architecture with an increased risk of developing cognitive 
impairment (CI) [67–70, 103–112].
When analyzing 12,926 documents from the PubMed, EMBase, ISI WebofScience and 
PsycINFO databases published before October 28, 2016, among 246,786 patients in 25,847, an 
average of 9.49 years was observed in dementia. The prognostic role of sleep disturbances, 
their subtypes (insomnia, OSAS, excessive sleepiness during the day, sleep disorders, and 
nonspecific sleeping problems) in the development of dementia were evaluated. Compared 
to those without sleep disorders, patients with sleep disorders had a higher risk of developing 
dementia. Subgroup analysis showed that insomnia increases the risk of developing AD, but 
not vascular dementia (VD). In contrast, OSAS was associated with a higher risk of early onset 
of SI, incl. AD and VD [105].
The relationship between the sleep architecture and the potential risk of developing CI in the 
community is considered on the basis of Framingham Heart Study (FHS). For 19 years’ study 
(the average follow-up period was 12 ± 5 years), there were 321 patients participating in Sleep 
Heart Health Study between 1995 and 1998, over the age of 60 at the time of sleep assessment. 
32 cases of dementia were traced; 24 cases were due to AD. After adjusting for age and sex, 
a low percentage of FSP and greater latency of REM sleep were associated with a higher risk 
of dementia. Each percentage reduction in FSP was associated with an increasing the risk of 
dementia by approximately 9% (p < 0.05). The relationship between the percentage of FSP and 
dementia was similar for the following adjustments for multiple covariates, including vascu-
lar risk factors, depressive symptoms, and drug use. The stages of slow wave sleep were not 
associated with the risk of dementia [106].
Among 96 patients in the acute period of IS, 79% of patients had heterogeneous post-stroke 
CI. In 21% of patients they had a dysmnestic character. The concentration of 6-SOMT was lower 
in patients with IS compared with the control. In the study of chronotypes, it was found that 
the majority of patients had an early variant, while the social jetlag value was 40 minutes. This 
indicator decreased with increasing age of patients. In most patients, IS developed in the morn-
ing, these patients had the lowest content of 6-SOMT in daily urine and the lowest values for 
MMSE. Potentially this is associated with a decrease in the protective activity of the melatonin. 
There was a correlation between chronobiological parameters and cognitive status. Thus, the 
expression of the “social jetlag” was associated with the semantic coding of memory, reflecting 
the function of the hippocampus. Patients with a late version of the chronotype were character-
ized by higher rates of delayed reproduction and semantic verbal fluency. With an increase in 
the social jostlag, the concentration of 6-SOMT in urine, probably compensatory, increased. The 
use of melaxen accelerated the recovery of CR, which had a positive effect on the rehabilitation of 
patients. It has been suggested that in elderly and senile patients, a high concentration of 6-SOMT 
in the acute period of IS was a marker of dysregulatory cognitive impairment, whereas its low 
content in the presence of a cognitive deficit may indicate a mixed, hippocampal type of CI [86].
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Possible prospects for the use of melatonin in elderly patients with CI are due to its antioxi-
dant, neuroprotective and nootropic effects. The positive effect of exogenous forms of melato-
nin on sleep in elderly patients is confirmed by the results of two placebo-controlled studies 
in which more than 500 patients over the age of 55, with primary insomnia [1107].
Using 6 mg of melatonin once a day before bedtime for 10 days in patients with moderate 
CI (MCI) led to significant improvement in memory and regression of depressive symptoms 
simultaneously with normalization of the sleep-wake cycle [103]. H. Jean-Louis et al. [108], 
Peck et al. [109], observed 26 patients with MCI syndrome received similar results. While 
1 mg melatonin administration just before sleep for 4 weeks, there was a significant decrease 
in forgetfulness in the auditory memory modality and improvement in night sleep compared 
with placebo. By Cardinali et al. there was made the retrospective analysis of the effect of 
melatonin therapy on cognitive functions, night sleep and wakefulness in 96 patients with 
MCI (61 patients received melatonin in doses of 3–9 mg once daily for 9–18 months). It has 
been proven that melatonin therapy contributes to significant cognitive improvement and 
regression of depressive symptoms [110].
The high efficiency of the combination of memantine and melatonin in the correction of MCI 
was shown in the experiment [111].
There is a discussion about the importance of light therapy in correcting of CI. Most of the 
studies demonstrate the stabilization of CR sleep-wakefulness and a reduction in the time of 
sleep in dementia with melatonin and light therapy [112].
The prevalence and correction of sleep disorders in patients with CVD need further study 
in randomized clinical trials in large groups of patients for understanding their impact and 
establishing cause-effect relationships in the development of CI. These investigations results 
will help to develop a treatment strategy.
5. Conclusion
Thus, literature data show that stroke has a peculiar organization in time. Тhe vegetative 
dysrhythmia and failure in the work of the Central control of biorhythms regulation play a 
key role in these processes.
The night sleep structure investigation is essential part in patients with stroke and patients 
with cardiovascular disease risk factors. The CR violation leads to the syndrome of desyn-
chronosis—mismatched dynamics of different indicators of the internal environment. This is 
a potential basis for the cerebrovascular and cardiovascular pathology.
Therefore, including the restoration of the CR with the chronotherapeutics methods is need 
for the vascular diseases prevention and treatment. Distribution of daily cases of stroke 
depends on individual properties of CR hemostasis and cerebral hemodynamics, and the 
specific of the night sleep structure of the of patients. In this regard, there must be a differenti-
ated approach in the treatment of “day” and “night” strokes. The main aspect of reducing the 
probability of primary and secondary cardiovascular “accidents” development should be the 
timely detection of sleep disorders and desynchronosis, as one of the leading risk factors. 
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The use of the personalized chronotherapeutics approaches allows to neutralize the negative 
impact of desynchronosis.
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